Nesina alogliptin regulatory update

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended that the agency add language about potential risks of heart failure to the labels of 2 dipeptidyl peptidase-4 ( DPP-4; CD26) inhibitors to treat diabetes -- Onglyza saxagliptin from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) and Nesina alogliptin from Takeda.

Read the full 480 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE